Efforts Aimed at Extending Cash Runway to mid-2019
LA JOLLA, Calif., July 5, 2018 /PRNewswire/ — Regulus Therapeutics, Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a strategic update and corporate restructuring. With the goal of extending its cash runway, Regulus has taken the following steps: recruitment activities for the RG-012 clinical program in Alport syndrome have been paused while discussions with Sanofi to potentially restructure the partnership are ongoing; preclinical research efforts will be focused on its Hepatitis B virus (HBV) programs; and a workforce reduction of approximately 60% is being implemented. …
Read the full article at: https://www.biospace.com/article/releases/regulus-announces-strategic-update-and-corporate-restructuring/